It has since been indicated that concomitant inhibition of SOS1 can improve sensitivity to MEK inhibition in a G12 and G13 mutant KRAS context, but this is not seen in KRAS-Q61 mutant cases of lung cancer. This evidence concerns the gene KRAS and lung carcinoma.